Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...